Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects

NCT ID: NCT06694168

Last Updated: 2024-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-27

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the efficacy of using L-PRF (leukocyte and platelet rich fibrin clot) as an autologous filling material in conjunction with the EPP (entire papilla preservation) technique for the treatment of interproximal intraosseous periodontal defects, compared to the same technique without L-PRF regarding clinical periodontal parameters and obtained radiographic parameters. It will also report possible postoperative complications and evaluate postoperative sensitivity. The main questions it aims to answer is:

• What is the effectiveness of LPR-F in conjunction with a complete papilla preservation (EPP) technique for the treatment of intrabony periodontal defects in CESA (health care center) patients in terms of clinical and radiographic periodontal parameters compared to the use of the same technique without L-PRF?

A non-randomized controlled clinical trial will be conducted on patients at CESA of the Universidad de los Andes. In 30 patients, 30 periodontal defects associated with a pocket with probing depths equal to or greater than 6 mm will be treated using the complete papilla preservation technique, either with L-PRF filling or without any filling material, assigned randomly to each intervention (15 participants in each group). Researchers will evaluate clinical and radiographic parameters at baseline and 6 months post-surgery. Patients will report their level of pain 24 hours and 7 days after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Periodontitis is an infectious disease of bacterial origin that leads to a slow and progressive loss of periodontal attachment, resulting in the destruction of supporting tissues and the formation of periodontal pockets. These pockets can be classified as suprabony or intrabony, with the latter being those where the bottom of the pocket is apical to the level of the adjacent alveolar bone and the bone loss presents a vertical pattern. Intraosseous defects affect 36% of periodontal patients and are particularly challenging to treat due to their association with greater loss of periodontal support, increased clinical attachment loss, deeper probing depths, greater tooth mobility, and functional consequences for the patient; thus, they have a less favorable prognosis and response to non-surgical periodontal treatment.

Lang et al. established that periodontal defects can be successfully treated with non-surgical therapy, limiting additional surgical interventions to sites with an initial probing depth of 6 mm or more, or to advanced periodontal lesions that, after a successful etiological phase, still retain residual pockets ≥ 6 mm. Given this, surgical periodontal therapy becomes a therapeutic alternative for intraosseous defects associated with advanced periodontal destruction, aiming to reduce tooth loss over time, recover lost periodontal support, and improve patient's quality of life.

Different surgical alternatives have been developed to enhance short- and long-term clinical outcomes in teeth with infrabony defects and reduced periodontal support. If the contour of the existing bone and the number of remaining bony walls are favorable, regenerative surgical therapy could successfully regenerate bone up to the level of the alveolar crest. The use of materials such as a demineralized allogeneic bone matrix in guided tissue regeneration has shown to achieve reductions in probing depths, gains in clinical attachment level, and filling of treated defects compared to defect instrumentation through open flap debridement.

However, these treatment modalities are sensitive to technique, and their outcomes depend on various factors including patient-dependent factors such as plaque control and smoking habits; site-specific factors, such as defect morphology; and factors inherent to the surgical techniques employed. Consequently, the failure of conventional surgical techniques, such as early exposure of the regenerated area, has been reported in the scientific literature and is even more frequent with the use of membranes and bone substitutes.

In light of this, innovations in flap design and soft tissue management have reduced failures associated with early wound closure. Surgical techniques such as simplified papilla flap and modified techniques, minimally invasive surgical technique (MIST), and modified minimally invasive surgical technique (M-MIST) have been designed to protect the regeneration site and facilitate the stability of the blood clot.

Recently, the complete papilla preservation technique has been proposed for treating intraosseous defects through regeneration, with a surgical approach designed to fully preserve the integrity of the interdental papilla, thus achieving an optimal environment for wound healing. Full access to the defect is achieved through a tunnel incision with vertical release and the elevation of a short flap on the contralateral side of the tooth associated with the defect. Then, enamel matrix derivatives and bone substitutes are applied to the defect to promote periodontal regeneration at the site. Although the evidence supporting the success of this technique is limited, in 2020 Aslan et al. compared the outcomes of using this technique with and without biomaterials for filling the defect. They reported no statistically significant differences in clinical attachment gain, probing depth reduction, or increase in gingival recession between the groups treated with the complete preservation technique and filling material or with the technique alone, respectively. They concluded that the use of this technique with and without regeneration materials resulted in improvements in the clinical and radiographic parameters of the treated defects.

The search for different materials with regenerative potential has led to the use of L-PRF (leukocyte and platelet rich fibrin), an autologous platelet-rich fibrin and leukocyte concentrate derived from blood that stimulates, enhances, and accelerates healing through a centrifugation process. The growth factors present in the concentrates, along with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes, and stem cells, L-PRF regulates the immune response by controlling inflammation, with a continuous release of growth factors and an analgesic effect, providing greater postoperative comfort to the patient. Additionally, being an autologous product significantly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs, and ease of preparation, it is widely used in the periodontal surgical field.

One of the goals of treating infrabony defects is the regeneration of soft and hard tissues, which is why using a complete papilla preservation surgical technique along with L-PRF as a biomaterial is a minimally invasive alternative to achieve this. The properties of L-PRF mentioned above will improve the biological conditions of the site and reduce postoperative complications, making its use in regenerative periodontal therapy worthy of deeper investigation. This is even more relevant given the lack of studies reporting the use of L-PRF associated with this surgical technique.

The aim of this study is to evaluate the efficacy of using a papilla preservation technique for the treatment of interproximal infrabony periodontal defects, with and without the additional use of L-PRF, concerning clinical and radiographic parameters. Its importance is based on the need in the field of periodontology to find minimally invasive, effective, and low-cost surgical techniques with the least amount of postoperative complications that allow for the treatment of infrabony defects in teeth affected by severe periodontitis, a growing public health issue. Improvements in clinical parameters through this procedure will translate into a greater likelihood of long-term tooth retention and an improvement in the patient's quality of life.

In order to achieve this, the following research question will be addressed: What is the efficacy of LPR-F in conjunction with a complete papilla preservation (EPP) technique for the treatment of infrabony periodontal defects in CESA patients in terms of clinical and radiographic periodontal parameters in comparison with the same technique, but without the use of L-PRF? All patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a probing depth of 3 mm in two or more teeth) will be included, who after re-evaluation 6 weeks after non-surgical periodontal therapy presented residual probing depths equal to or greater than 6 mm associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph. Patients with underlying untreated pathologies such as diabetes and hypertension, patients taking medications that interfere with the healing process such as bisphosphonates, diseases that alter bone metabolism such as osteoporosis, and pregnant or breastfeeding women will be excluded. 30 patients (30 defects) will be randomly allocated into an interventional group for the treatment of the infrabony defect. One group will be treated with an EPP technique using L-PRF as the defect filling material and the other group will be treated with the same technique, but with no biomaterial to fill the defect.

The clinical parameters that will be evaluated in each group will be: O'Leary Bacterial Plaque Index (PI), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL), gingival margin position (GMP), distance from the interproximal contact point to the papilla tip (PP), papilla width (PW), and keratinized gingiva width (KW). These parameters will be measured before the surgical procedure and 6 months after surgery.

The radiographic measurements will be obtained by calibrated operators and will be analyzed in all subjects from a CBCT performed before surgical treatment and 6 months postoperatively. The infrabony component of the defect (INFRA) will be measured, allowing the calculation of the defect filling percentage after surgery (%DF). Additionally, measurements of the mesiodistal width (M-D) and buccal-palatal/lingual width (B-P/L) will be obtained. Researchers will evaluate clinical and radiographic parameters at baseline and 6 months post-surgery. Patients will report their level of pain 24 hours and 7 days after surgery.

The relevance of the present study is based on the need in the field of periodontics to find minimally invasive, effective and low-cost surgical techniques with the least amount of post-surgical complications that will successfully treat infrabony defects of teeth affected by severe periodontitis, a growing public health issue. Improvements in clinical parameters through this procedure will result in a greater likelihood of long-term tooth retention and an improvement in quality of life for the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Regeneration Minimally Invasive Surgical Technique Platelet Rich Fibrin Microsurgery Periodontal Intrabony Defect Periodontal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

To calculate the sample size, statistically significant EVA values were taken from a previous series of cases in the same line of research. The values were analyzed using STATA software, resulting in an N of 26 patients (26 defects). Finally, a final N of 30 defects to be treated was established (1 defect per patient), overestimating the initial N in case of possible losses during the follow-up period. If there is more than one site per patient that needs to be treated, it will be decided randomly which site will be included in the study, treating all sites with the same technique.

The sample was randomized using the digital STATA software, separating the sample into sites to be treated using the EPP technique with defect filling using LPRF (15 defects) and sites to be treated with the same technique but without LPRF (15 defects).
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EPP with L-PRF as a filling material

This group will have the infrabony defect treated with the use of an EPP minimally invasive technique and the defect will be filled with L-PRF.

Group Type EXPERIMENTAL

Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery

Intervention Type PROCEDURE

The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.

REGEND001 Autologous Therapy Product

Intervention Type PROCEDURE

L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.

EPP with no defect filling material

This group will have the infrabony defect treated with the use of an EPP minimally invasive technique, but the defect will not be filled with L-PRF.

Group Type ACTIVE_COMPARATOR

Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery

Intervention Type PROCEDURE

The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery

The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.

Intervention Type PROCEDURE

REGEND001 Autologous Therapy Product

L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a PD \>3 mm in two or more teeth) will be included.
* After re-evaluation (6 weeks after non-surgical periodontal therapy) presented residual probing depths equal to or greater than 6 mm.
* Residual pocket is associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph.

Exclusion Criteria

* Patients with an underlying decompensated pathology such as diabetes and hypertension.
* Patients taking medications that interfere with the healing process such as bisphosphonates.
* Patients with diseases that alter bone metabolism such as osteoporosis.
* Pregnant or breastfeeding women.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad de los Andes, Chile

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas G Anwandter, DDS

Role: PRINCIPAL_INVESTIGATOR

Universidad de Los Andes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CESA (centro de salud de la clínica odontológica de la Universidad de los Andes)

Santiago, San Bernardo, Chile

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andreas G Anwandter, DDS

Role: CONTACT

+56225891100 ext. +562

Antonio Sanz, DDS

Role: CONTACT

+56225891173 ext. +562

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Guillermo E Salgado, DDS

Role: primary

+56225891100 ext. +562

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEC2024045

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Growth Factors Release of PRF and PRGF
NCT02447510 COMPLETED PHASE3